Literature DB >> 17250725

Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease.

E N Kapaki1, G P Paraskevas, N G Tzerakis, C Sfagos, A Seretis, E Kararizou, D Vassilopoulos.   

Abstract

The aim of the present study was the quantitation of total tau protein (tau(T)), tau phosphorylated at threonine 181 (tau(P-181)) and beta-amyloid(1-42) (Abeta42) in the cerebrospinal fluid (CSF) of patients with idiopathic normal pressure hydrocephalus (iNPH), Alzheimer's disease (AD) and controls. Double sandwich ELISAs (Innogenetics) were used for the measurements. Total tau was significantly increased in iNPH and highly increased in AD as compared with the control group, whilst Abeta42 was decreased in both diseases. CSF tau(P-181) levels were significantly increased only in AD, but not in iNPH as compared with the controls. A cut-off level for tau(T) at 300 pg/ml, successfully discriminated AD from normal aging with a 95.8% specificity and 91% sensitivity; whilst the tau(P-181)/tau(T) ratio (cut-off value 0.169) was more specific (100%) but less sensitive (92.5%). For the discrimination of iNPH from AD tau(T) achieved low specificity (77.8%) but high sensitivity (92.5%), whilst tau(P-181) (cut-off value 47.4) was both sensitive and specific (88.7% and 86.7% respectively) for the discrimination of these disorders. The present study, despite being clinical, supports the notion that CSF tau(P-181) alone or in combination with tau(T) may be a useful marker in the discrimination of iNPH from AD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17250725     DOI: 10.1111/j.1468-1331.2006.01593.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  47 in total

Review 1.  A review of cognitive impairment and differential diagnosis in idiopathic normal pressure hydrocephalus.

Authors:  Marta Picascia; Roberta Zangaglia; Sara Bernini; Brigida Minafra; Elena Sinforiani; Claudio Pacchetti
Journal:  Funct Neurol       Date:  2015 Oct-Dec

2.  γ-secretase binding sites in aged and Alzheimer's disease human cerebrum: the choroid plexus as a putative origin of CSF Aβ.

Authors:  Fei Liu; Zhi-Qin Xue; Si-Hao Deng; Xiong Kun; Xue-Gang Luo; Peter R Patrylo; Gregory M Rose; Huaibin Cai; Robert G Struble; Yan Cai; Xiao-Xin Yan
Journal:  Eur J Neurosci       Date:  2013-02-22       Impact factor: 3.386

Review 3.  CSF biomarkers for amyloid and tau pathology in Alzheimer's disease.

Authors:  Hanna Rosenmann
Journal:  J Mol Neurosci       Date:  2011-11-05       Impact factor: 3.444

4.  Prognostic value of amyloid PET scan in normal pressure hydrocephalus.

Authors:  Hyemin Jang; Seong Beom Park; Yeshin Kim; Ko Woon Kim; Jung Il Lee; Sung Tae Kim; Kyung Han Lee; Eun-Suk Kang; Yeong Sim Choe; Sang Won Seo; Hee Jin Kim; Yeo Jin Kim; Cindy W Yoon; Duk L Na
Journal:  J Neurol       Date:  2017-11-11       Impact factor: 4.849

5.  Alzheimer CSF biomarkers may be misleading in normal-pressure hydrocephalus.

Authors:  Neill R Graff-Radford
Journal:  Neurology       Date:  2014-10-21       Impact factor: 9.910

6.  SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease.

Authors:  Carlos Cruchaga; John S K Kauwe; Kevin Mayo; Noah Spiegel; Sarah Bertelsen; Petra Nowotny; Aarti R Shah; Richard Abraham; Paul Hollingworth; Denise Harold; Michael M Owen; Julie Williams; Simon Lovestone; Elaine R Peskind; Ge Li; James B Leverenz; Douglas Galasko; John C Morris; Anne M Fagan; David M Holtzman; Alison M Goate
Journal:  PLoS Genet       Date:  2010-09-16       Impact factor: 5.917

Review 7.  Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.

Authors:  Christopher D Aluise; Renã A Sowell; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2008-08-07

Review 8.  Total and phosphorylated tau protein as biological markers of Alzheimer's disease.

Authors:  Harald Hampel; Kaj Blennow; Leslie M Shaw; Yvonne C Hoessler; Henrik Zetterberg; John Q Trojanowski
Journal:  Exp Gerontol       Date:  2009-10-22       Impact factor: 4.032

9.  Genetic discoveries in AD using CSF amyloid and tau.

Authors:  Carlos Cruchaga; Mark T W Ebbert; John S K Kauwe
Journal:  Curr Genet Med Rep       Date:  2014-03-01

10.  Low levels of amyloid-beta and its transporters in neonatal rats with and without hydrocephalus.

Authors:  Kelley E Deren; Jennifer Forsyth; Osama Abdullah; Edward W Hsu; Petra M Klinge; Gerald D Silverberg; Conrad E Johanson; James P McAllister
Journal:  Cerebrospinal Fluid Res       Date:  2009-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.